Navigation Links
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
Date:3/3/2008

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced its financial results for 2007 and provided an overview of its activities during the year. NicOx also announced today the initiation of two large Ambulatory Blood Pressure Monitoring (ABPM) studies for naproxcinod (see separate press release).

Key highlights 2007:

-- Initiation of the two remaining pivotal phase 3 trials for naproxcinod

(the 302 and 303 studies) and completion of enrollment in the 302 study

-- Presentation of the naproxcinod phase 3 results at the American College

of Rheumatology (the 301 study) and data from an Ambulatory Blood

Pressure Monitoring trial at the American Heart Association (the 104

study)

-- Initiation of a phase 2 proof-of-concept study designed to compare the

safety and efficacy of PF-03187207 to Pfizer Inc's Xalatan

-- Start of clinical development for the first nitric oxide-donating

antihypertensive by Merck & Co., Inc.

-- Initiation of a phase 2 proof-of-concept study for TPI 1020 in Chronic

Obstructive Pulmonary Disease (COPD), following promising top-line

results in a phase 2a study in asthmatic smokers

-- Establishment of NicOx' United States (U.S.) headquarters in Warren,

New Jersey, as a base for Commercial Affairs and Clinical Operations in

North America

-- Strengthening of the Company's executive management team, through the

appointment of Pascal Pfister, MD as Chief Scientific Officer (CSO),

and Sanjiv Sharma as Vice President Commercial Affairs

"We envision that 2008 will be a transformational year for NicOx. We expect to complete the pivotal phase 3 program for naproxcinod, including a pooled analysis of the Office Blood Pressure Measurements, ahead of a projected New Drug Application filing in mid-2009," said Michele Garufi, Chair
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ctober 7 /-,Sosei Group Cor...ctura,Group plc ("Vectura"; LSE: VEC), announce re...acy, safety and tolerability of NVA237 presented a...Society (ERS) in Berlin,Germany. The new data sho...haled long-acting muscarinic antagonist (LAMA), pr...
(Date:10/6/2008)...to the understanding of and possible trea...BILLERICA, Mass., Oct. 6 /- Seahorse ...t ever analytical instrument for the,kinetic measu...oplasmic,glycolysis in cells in a 96 well micropla...ular bioenergetics have been relatively unchanged ...
(Date:10/6/2008)... at The American College of Nutrition ...6 /- New research on the benefits of,...t The American College of,Nutrition (ACN) Annual M...Probiotics in Health and Disease." Scientific expe...ion discussed the potential uses for,probiotics in...
(Date:10/6/2008)...E, Oct. 6 /- Complete,Genomics Inc., ...quencing,company, and the Institute for Systems Bi...onduct populationwide human genome studies., In p...e its proprietary,DNA sequencing technology to seq...hen, once proof-of-concept has been demonstrated, ...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 2'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 3'Friendly' Bacteria Can Benefit Health Throughout the Lifecycle 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 1New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 2New study in the journal Sleep finds that catathrenia can be successfully treated with CPAP 8958 3Journal Sleep 3A A short term dose of zolpidem is an effective treatment for insomnia 8956 1Journal Sleep 3A A short term dose of zolpidem is an effective treatment for insomnia 8956 2Research suggests new treatment suitable for all patients 8954 1Research suggests new treatment suitable for all patients 8954 2Research suggests new treatment suitable for all patients 8954 3Silence may lead to phantom noises misinterpreted as tinnitus 8952 1
(Date:10/7/2008)... Moores Cancer Center at the University of Califor...ave off the relentless march of advanced lung canc...r vaccine. While many vaccines attempt to pump up ...accine, Lucanix, is genetically engineered to also...em-suppressing activities. , The first patients ...
(Date:10/7/2008)...ment of planned bequest comes at stem cell symposi...re/ -- Just over one year,ago, retail pioneer A. A...University of Michigan, to endow a new research in...nting human disease., Today, at the institute,s f... he will bequeath an additional $22 million to the...
(Date:10/7/2008)...0 PEOPLE ACROSS THE NATION HAVE SAID ,I VOTE FOR T...S, Oct. 7 /PRNewswire/ -- To aid and help educate ... positions of presidential candidates,Senators Joh...ancer issues,the Susan G. Komen for the Cure(R) A...ces available on its web site --, http://www.IVote...
(Date:10/7/2008)... Wyndstorm Corporation ( www.wyndstorm.com ) ...ompany, announced a key win with Muve, Inc. ( www....plan program design to promote Muve,s activity-bas...project will ultimately help Muve,s corporate clie...oyees via interactive messaging, rewards programs,...
Breaking Medicine News(10 mins):Health News:Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center 2Health News:Alfred Taubman Announces New $22M Gift to U-M 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Educates Voters, Debate Watchers on McCain/Obama Health Care Agendas 3Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3
...claim to the highest autism rate in America, have ...to autism and provide lifetime care for those wit...utism, the largest so far, has found that about 1 ...est rate 1 in 94 children found in New Jersey. ...
...tronic nose device which may be used to diagnose t...s at Leiden University Medical Center in the Nethe... a newer version of a sensor that has been used in...es, contains chemical vapour sensors that react to...
...male impotence drug Viagra may be useful for treat...r the treatment of high blood pressure and angina,...levels of a naturally-occurring compound, cyclic g...GMP). In the brain, cGMP has a vital function in ...
...that topical application of a gel made from platel...ds heal more quickly and completely . Recent inno... into a concentrated plasma rich in platelets (par...), and then to an autologous (from the patients ow...
Other Medicine News:Health News:American State Lawmakers Make Moves To Tackle Autism 2Health News:Electronic Nose to Diagnose the Severity of Asthma 2Health News:Gel Made of Patients Own Platelets may Speed Up Wound Healing 2
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: